Patients routinely require multiple lines of systemic therapy to address the ongoing burden of cGVHD1

A prospective, multicenter, observational study, which included 250 adult patients who underwent an alloHCT and subsequently received treatment for cGVHD, demonstrated that1

  • Patients received a median of 3 lines of systemic therapy, and the median time to permanent discontinuation of IST was 69 months
  • Progressive disease or lack of improvement was the reason 86% of patients required the initiation of new treatments, indicating a lack of cGVHD control with previous lines of systemic therapy
  • More than half of patients who discontinued IST at least 1 time had to restart IST within a median of 3.4 months
  • Of the patients attempting a first-time discontinuation of IST, 23% did so only after ≥3 lines of systemic therapy
Circle icon with greater than 70% in the center

of patients with cGVHD require additional treatment following initial therapies.2

Patients with cGVHD often have poor QOL, regardless of disease severity3

The clinically significant reductions in QOL that can occur with all severity grades (mild through severe) of cGVHD may be underestimated by physicians.3

The burden of cGVHD is multifaceted, with patients experiencing poor QOL and progressive disability3,4,a

Circular icon with bar graph showing decreasing value

QOL scores across all domains are lower in patients with greater cGVHD severity.3

  • Even patients with mild cGVHD symptoms in the lungs, GI tract and joints/fascia have clinically meaningful deterioration in physical QOL

aIn a national cross-sectional questionnaire study conducted in Japan, VAS scores were evaluated using 1140 pairs of patient and physician questionnaires. The data were collected from recipients of alloHCT for hematologic disease between 1995 and 2009. The VAS was used to assess the physical, psychological and social QOL of long-term survivors of alloHCT (median time post alloHCT of 7 years) who had various degrees of cGVHD severity.3

evaluated in a real-world demographicb of patients with cGVHD.5,6

aGVHD, acute graft-versus-host disease; alloHCT, allogeneic hematopoietic cell transplant; cGVHD, chronic graft-versus-host disease; ECP, extracorporeal photopheresis; GI, gastrointestinal; IST, immunosuppressive therapy; MOA, mechanism of action; NIH, National Institutes of Health; PPI, proton pump inhibitor; QOL, quality of life; VAS, visual analog scale.

bROCKstar study select baseline patient characteristics (200-mg once-daily arm): median age of 53 years (range, 21-77); male, n=42 (64%); median of 3 prior lines of systemic therapy; median of 25 months (range, 2-162) from cGVHD diagnosis to enrollment; median prednisone-equivalent dose at enrollment of 0.20 mg/kg/d (range, 0.03-0.95); concomitant PPI use, n=33 (50%); ≥4 organs involved, n=33 (50%); previous aGVHD, n=42 (64%); refractory to prior line of systemic therapy, n=44 (79%)c; NIH-defined disease severity: n=46 (70%) severe, n=18 (27%) moderate, n=2 (3%) mild. Prior systemic therapies included corticosteroids (prednisone), n=65 (99%); tacrolimus, n=40 (61%); ECP, n=31 (47%); ibrutinib, n=22 (33%); and ruxolitinib, n=20 (30%).6,7
cDenominator excludes patients with unknown status.5

References: 1. Lee SJ, Nguyen TD, Onstad L, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555-562. doi:10.1016/j.bbmt.2017.10.042 2. Bachier CR, Aggarwal SK, Hennegan K, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transplant Cell Ther. 2021;27(6):504.e1-504.e6. doi:10.1016/j.jtct.2020.12.027 3. Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(10):1749-1758. doi:10.1016/j.bbmt.2017.06.011 4. Hamilton BK, Storer BE, Wood WA, et al. Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(4):772-777. doi:10.1016/j.bbmt.2019.10.019 5. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC. 6. Cutler C, Lee SJ, Arai S, et al; on behalf of the ROCKstar Study Investigators. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278-2289. doi:10.1182/blood.2021012021 7. Data on file 1. Kadmon Pharmaceuticals, LLC; 2021.